/ /

  • linkedin
  • Increase Font
  • Sharebar

    Intravitreal bevacizumab: Improved vascular pattern after treatment in ROP

    Fluorescein angiography is safe and effective method to follow-up these patients


    Take-home message: After intravitreal bevacizumab injection in eyes with treatment requiring-retinopathy of prematurity, there was growth and maturation of retinal vessels, although certain abnormalities remained.



    Mexico City—Anti-vascular endothelial growth factor (VEGF) therapy has been initiated recently for the treatment of retinopathy of prematurity (ROP).

    However, no studies have described the retinal angiographic findings in patients treated with intravitreally administered bevacizumab (Avastin, Genentech), said Andrée Henaine-Berra, MD.

    Previous studies dating back to 1971 and others performed more recently have described the angiographic characteristics in eyes with ROP, and the angiographic findings in eyes with this disease before and after they underwent laser treatment.

    These studies showed that fluorescein angiography is safe and useful for studying the maturation of vessels in the premature retina, said Dr. Henaine-Berra, attending physician at the Retina Department, Hospital General “Dr. Manuel Gea González,” in Mexico City, Mexico.

    Effects of bevacizumab

    Dr. Henaine-Berra and colleagues studied 26 patients (47 eyes; 16 girls, 10 boys) in a prospective, nonrandomized case series from January 2008 to December 2012, recruited at Hospital “Dr. Luis Sánchez Bulnes,” Asociacion para Evitar la Ceguera en Mexico, Mexico City.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results